GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (FRA:12X1) » Definitions » 6-1 Month Momentum %

Anavex Life Sciences (FRA:12X1) 6-1 Month Momentum % : -21.34% (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-27), Anavex Life Sciences's 6-1 Month Momentum % is -21.34%.

The industry rank for Anavex Life Sciences's 6-1 Month Momentum % or its related term are showing as below:

FRA:12X1's 6-1 Month Momentum % is ranked worse than
67.87% of 1522 companies
in the Biotechnology industry
Industry Median: 4.02 vs FRA:12X1: -21.34

Competitive Comparison of Anavex Life Sciences's 6-1 Month Momentum %

For the Biotechnology subindustry, Anavex Life Sciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's 6-1 Month Momentum % falls into.



Anavex Life Sciences  (FRA:12X1) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anavex Life Sciences  (FRA:12X1) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Anavex Life Sciences 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (FRA:12X1) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (FRA:12X1) Headlines

No Headlines